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Abstract
Introduction: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian
surface epithelial cancer.
Case presentation: A 69-year-old postmenopausal woman presented with a 2-year history of progressive
enlargement of an abdominal mass. Abdominal computed tomography showed a pelvic mass. CA-125 was normal.
A staging operation with total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy
and pelvic lymph node dissection was performed. After surgery, the pathologic report of the right ovarian tumour
was TCC, grade 3, stage IC. The patient underwent 3 cycles of chemotherapy: carboplatin and paclitaxel. She is
regularly followed up and has been disease free for 10 months
Conclusion: Transitional cell carcinoma (TCC) of the ovary is a rare subtype of epithelial ovarian cancer. Surgical
resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other
types of ovarian cancers.
Introduction
Transitional cell carcinoma (TCC) of the ovary is a rare,
recently recognized, subtype of ovarian surface epithelial
cancer. In a study by Silva et al, focal or diffuse TCC
pattern was seen in 88 of 934 ovarian cancers [1]. Here,
we present a case of TCC of the ovary, managed by
total abdominal hysterectomy and bilateral salpingo-
oophorectomy with infracolic omentectomy and pelvic
lymph node dissection followed by chemotherapy.
Case presentation
A 69-year-old postmenopausal woman presented with a
2-year history of progressive enlargement of an abdom-
inal mass. She had experienced weight loss of about 4 kg
during the 6 months prior to admission. Physical exami-
nation showed a pelvic mass. Abdominal ultrasound
showed a pelvic mass measuring 31 × 35 mm with homo-
geneous echogenicity. Abdominal computed tomography
(CT) showed a homogeneous cyst on the right side of the
pelvis, which was larger than 35 mm in maximal dia-
meter with a solid component. There was no evidence of
lymphadenopathy. The liver and kidneys were unremark-
able (Figure 1). Routine biologic test results were all
within normal ranges. Initial investigation of tumor mar-
kers before surgery showed normal serum CA-125
(5.3 U/mL; normal, 0-35 U/mL). She underwent surgery
under the impression of malignant ovarian tumor.
A small amount of ascites (about 100 mL) in the pelvic
cavity was found intraoperatively. A cystic mass, measur-
ing 3, 5 × 1.5 cm, arising from the right ovary; was
resected. There was no enlargement of the paraaortic
lymph node on palpation. Therefore, surgical staging
procedures including total abdominal hysterectomy,
bilateral salpingo-oophorectomy, infracolic omentectomy
and pelvic lymph node dissection were performed. The
ascites was also sent for cytologic examination. Micro-
scopic examination showed malignant transitional
epithelial lining of the right ovarian cyst. There was no
metastatic lesion and the cytology of the ascites was posi-
tive. The final diagnosis was TCC, grade 3, stage IC
(Figure 2). Immunohistochemical studies showed that
the tumor was positive for cytokeratin 7 and CA 125
(Figure 3) and negative for CK20. The patient received
postoperative chemotherapy with carboplatin (area under
the curve, 5) and paclitaxel (175 mg/m2) every 3 weeks
for three cycles because stage Ic. The patient is being
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10 months.
Conclusions
Epidemiology and Description
TCC of the ovary is a recently recognized subtype of
ovarian surface epithelial cancer. It has been described as
a primary ovarian carcinoma in which definite urothelial
features are present but no benign, metaplastic and/or
proliferating Brenner tumor can be identified. TCC of
the ovary was first defined by Austin and Norris [2].
They reported a group of patients who had ovarian
tumors presenting with histologic features similar to
those seen in a malignant Brenner tumor, but the tumors
lacked the associated benign Brenner tumor component.
Pure TCC was thus distinguished from malignant Bren-
ner tumor. In addition to not having a benign Brenner
tumor component, TCC lacks the prominent stromal cal-
cification [2]. The true incidence of TCC of the ovary
remains unknown. Because TCC of the ovary has close
morphologic similarities to TCC of the bladder and it
behaves more aggressively than malignant Brenner
tumor, Austin and Norris concluded that ovarian TCC
arises directly from the pluripotential surface epithelium
of the ovary and from cells with urothelial potential,
rather than from a benign or proliferative Brenner tumor
precursor. The metastatic pathways of the tumor are
mimicking the transitional cell carcinoma of the bladder
wich implicate a loss of the integrity of E-cadherin [2].
Diagnosis
As described in detail by Eichhorn and Young, ovarian
TCC typically showed undulating, diffuse, insular and tra-
becular growth patterns [3]. The tumor cell nuclei were
oblong or round, often exhibiting nucleoli or longitudinal
grooves. The cytoplasm was often pale and granular, rarely
clear or eosinophilic. The common presenting symptoms
of TCC of the ovary are abdominal pain, abdominal swel-
ling or distension, and weight loss. Occasionally, the
patient may present with uterine bleeding, back pain,
bowel or urinary symptoms. The clinical presentation is
indistinguishable from other types of ovarian carcinoma
[2,3]. CA-125 is clinically useful as a serum marker of
tumor progression and recurrence.
Histopathology and immunochemistry
The immunophenotype of TCC of the ovary is similar
to that of other surface carcinomas of the ovary, but
Figure 1 Abdominal computed tomography shows homo-
geneous cyst on the right side of the pelvis, which was larger
than 35 mm in maximal diameter with a solid component.
Figure 2 Ovarian transitional cell carcinoma. (hematoxylin &
eosin, 40×).
Figure 3 Immunohistochemical staining of ovarian transitional
cell carcinoma. Tumor cells are positive for cytokeratin 7.
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ovarian TCCs are negative for CK20, thrombomodulin
(TM) and uroplakin III, which are the antigens that are
usually (CK20) or sometimes (TM and uroplakin III)
detected in bladder TCCs. Unlike bladder TCCs, ovarian
TCCs are often positive for vimentin, CA-125 and
Wilms tumor protein (WT1)[3]. Croft et al concluded
that almost all of the ovarian TCCs marked strongly
for estrogen receptors (ERs), a characteristic that may
help to differentiate these lesions from papillary urothe-
lial carcinoma metastatic to the ovary [4]. Shen et al
described that overexpression of p53 in TCC of the
ovary was associated with a poor prognosis [5]. How-
ever, Gershenson et al. concluded that immunostaining
for p53, epidermal growth factor receptor, HER-2/neu,
DNA ploidy, and S-phase fraction did not distinguish
TCC from other common epithelial ovarian cancers
[6,7]. TCC of the ovary is reported to be sensitive to cis-
platin-based chemotherapy and has a better prognosis
than other types of common epithelial tumors of the
ovary. Sweeten et al. suggested that TCC may be more
chemosensitive than other common epithelial tumors in
the refractory setting [8].
Prognosis
The relative influences of tumor biology and treatment
strategies remain undetermined. Gershenson et al. con-
cluded that advanced-stage ovarian TCC was significantly
more chemosensitive and associated with better prognosis
than poorly differentiated serous carcinoma [9]. Kommoss
et al also documented that patients with TCC had better
prognoses compared to patients with all other types of
ovarian carcinomas after standardized chemotherapy[10].
Treatment
Optimal surgical resectability followed by cisplatin-based
chemotherapy might contribute to the survival benefit
[10]. In their study, Silva et al reported that the esti-
mated 5-year survival rate after surgery for 88 patients
was 37%, whereas for patients who received chemother-
apy, it was 41% [1]. Factors associated with survival for
patients who received chemotherapy were the clinical
stage, the percentage of TCC component in the primary
tumor, and the results of the second-look operation.
The predominance of TCC was a favorable prognostic
factor and patients with higher clinical stages had
poorer prognoses.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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